Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00285012 · ClinicalTrials.gov registry record · Phase 3

Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).

A Phase 3 study of Smoking Cessation, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
504
Enrollment target
20
Study locations

NCT00285012 is a Phase 3 study of Smoking Cessation that has completed, run by Pfizer. The registered enrollment target is 504 participants, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target. The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00285012, a Phase 3 study of Smoking Cessation, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
504 participants
Enrollment target
20
Study locations

Study Summary

This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.

Conditions Studied

Smoking Cessation

Interventions

  • DRUG placebo
  • DRUG Varenicline Tartarate

Study Locations (20)

North Carolina

  • Pfizer Investigational Site - Chapel Hill
  • Pfizer Investigational Site - Chapel Hill
  • Pfizer Investigational Site - Raleigh
  • Pfizer Investigational Site - Winston-Salem
  • Pfizer Investigational Site - Winston-Salem

California

  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Los Angeles

Connecticut

  • Pfizer Investigational Site - Farmington
  • Pfizer Investigational Site - Farmington

Alabama

  • Pfizer Investigational Site - Birmingham

Colorado

  • Pfizer Investigational Site - Denver

Florida

  • Pfizer Investigational Site - Miami

Kentucky

  • Pfizer Investigational Site - Lexington

Maine

  • Pfizer Investigational Site - Portland

Trial Details

FieldValue
Enrollment Target 504 participants
Start Date 2006-05
Est. Completion 2009-04
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00285012

The ClinicalTrials.gov registry entry for NCT00285012 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 504 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00285012 reports 20 study locations spanning 14 distinct geographic areas - top geographies include North Carolina, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00285012 about?

NCT00285012 is a clinical study titled "Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).". This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.

What is the current status of trial NCT00285012?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 504 participants. The study started on 2006-05. Estimated completion is 2009-04.

What conditions does trial NCT00285012 study?

This clinical trial studies the following conditions: Smoking Cessation.

What interventions are being tested in trial NCT00285012?

The interventions under investigation include: placebo (DRUG), Varenicline Tartarate (DRUG).

Who is sponsoring clinical trial NCT00285012?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00285012 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Smoking Cessation

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.